SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

What starts as breathlessness can turn fatal within minutes, doctors warn that quick action, correct inhaler use and timely ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Small New Year's resolutions could make a big difference in the severity of people allergies and asthma, according to an ...

Episodic respiratory symptoms are especially common in children between ages 0 and 2 years and are not necessarily an indicator of childhood asthma. The greatest risk factor for progression from ...

Atopic adult-onset asthma, which is defined as initiating in patients age 18 years or older, is the most common asthma phenotype observed in clinical practice. In many cases, adult-onset asthma begins ...

Please provide your email address to receive an email when new articles are posted on . “Asthma care in the Netherlands is divided between different health care providers, including respiratory ...

As the prevalence of asthma continues to increase, the financial impact on the healthcare costs of the United States does as well. Managed care pharmacists are ideally situated to unite the shared ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

The treatment, which will be sold under the brand name Exdensur, is an “ultra-long-acting” version of a biologic treatment ...

Children with asthma who were insured by Medicaid were significantly less likely to receive specialist care over a 1-year period than children with private insurance, based on claims data from nearly ...